The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 12, 2019

Filed:

Feb. 04, 2019
Applicant:

The Scripps Research Institute, La Jolla, CA (US);

Inventors:

Matthew D. Disney, Jupiter, FL (US);

Suzanne G. Rzuczek, Jupiter, FL (US);

Assignee:

The Scripps Research Institute, La Jolla, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/10 (2006.01); A61K 31/496 (2006.01); A61K 31/702 (2006.01); A61K 38/07 (2006.01); A61K 38/08 (2019.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/702 (2013.01); A61K 38/07 (2013.01); A61K 38/08 (2013.01); A61K 47/549 (2017.08); A61K 47/55 (2017.08); A61K 47/557 (2017.08);
Abstract

Potent modulators of RNA function can be assembled in cellulo by using the cell as a reaction vessel and a disease-causing RNA as a catalyst. When designing small molecule effectors of function, a balance between permeability and potency must be struck. Low molecular weight compounds are more permeable while higher molecular weight compounds are more potent. The advantages of both types of compounds could be synergized if low molecular weight molecules could be transformed into potent, multivalent ligands via a reaction catalyzed by binding to a target in cells expressing a genetic defect. We demonstrate that this approach is indeed viable in cellulo. Small molecule modules with precisely positioned alkyne and azide moieties bind adjacent internal loops in r(CCUG), the causative agent of myotonic dystrophy type 2 (DM2), and are transformed into oligomeric, potent inhibitors of DM2 RNA dysfunction via a 1,3 Huisgen dipolar cycloaddition reaction, a variant of click chemistry. Additionally, we show that this approach is applicable to the r(CUG) repeating RNA that causes myotonic dystrophy type 1 (DM1). The click chemistry approach also allows for FRET sensors to be synthesized on-site by using r(CUG) repeats as a catalyst. Furthermore it is shown that small molecule binding sites in patient-derived cells can be identified by using reactive approaches termed Chem-CLIP and Chem-CLIP-Map. Lastly, it is shown that small molecules that target r(CUG) expansions can be designed to cleave this RNA by appending a small molecule with a nucleic acid cleaving module.


Find Patent Forward Citations

Loading…